Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

Piper Sandler raised the firm’s price target on Halozyme (HALO) to $53 from $52 and keeps a Neutral rating on the shares after maintaining FY24 ...

H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $70 from $68 and keeps a Buy rating on the shares. The company has strong ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

Wells Fargo has recently reduced Halozyme Therapeutics, Inc. (HALO) stock to Equal Weight rating, as announced on October 7, 2024, according to Finviz. Earlier, on September 19, 2024, JP Morgan had ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Halozyme (HALO) announced that Argenx’s (ARGX) Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Health ...